DUSKA THERAPEUTICS, INC. AMENDMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • March 31st, 2009 • Cordex Pharma, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 31st, 2009 Company IndustryTHIS AMENDMENT (the Amendment") TO THE NON-QUALIFIED STOCK OPTION AGREEMENT (the "Original Agreement") dated as of the 26th day of September, 2007 by and between Duska Therapeutics, Inc., a Nevada corporation (the "Company"), and James S. Kuo ("Optionee") is effective as of the 10th day of November, 2008.
DUSKA THERAPEUTICS, INC. AMENDMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • March 31st, 2009 • Cordex Pharma, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 31st, 2009 Company IndustryTHIS AMENDMENT (the “Amendment") TO THE NON-QUALIFIED STOCK OPTION AGREEMENT (the "Original Agreement") dated as of the 26th day of September, 2007 by and between Duska Therapeutics, Inc., a Nevada corporation (the "Company"), and James S. Kuo ("Optionee") is effective as of the 10th day of November, 2008.
STRATEGIC MASTER SERVICES AGREEMENTStrategic Master Services Agreement • March 31st, 2009 • Cordex Pharma, Inc. • Biological products, (no disgnostic substances) • North Carolina
Contract Type FiledMarch 31st, 2009 Company Industry JurisdictionThis Strategic Master Services Agreement (this “Agreement”) is made as of January 22, 2009 (the “Effective Date”) by and between Cato Holding Company d/b/a Cato BioVentures, a North Carolina corporation (“CBV”), and Cordex Pharma, Inc., a Nevada corporation (“Cordex”). Each of CBV and Cordex may be referred to herein separately as a “Party” and collectively as the “Parties.” As used in this Agreement, “Affiliates” means any corporation, firm, partnership, or other entity which is controlled by or is under common control with a Party. For the purpose of this definition, “control” shall mean the power to direct, or cause the direction of, the management and policies of an entity through the ownership of at least fifty percent (50%) of the voting share capital of such entity or any other comparable equity, by contract, or by ownership interest.